Lesson plan
Bimagrumab
Bimagrumab (BYM338) is a human monoclonal antibody first developed by Novartis and currently by Eli Lilly to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B. Bimagrumab must be administered intravenously at a hospital or clinic. The medication has a long half-life and is administered once a month.
Article summary
Bimagrumab (BYM338) is a human monoclonal antibody first developed by Novartis and currently by Eli Lilly to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B. Bimagrumab must be administered intravenously at a hospital or clinic. The medication has a long half-life and is administered once a month.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.